High-purity, plasma-derived, pasteurized Factor VIII concentrates in the treatment of patients with haemophilia A: update of a long-term pharmacovigilance study

被引：0
|
作者：
Klamroth, Robert [1 ]
Holzhauer, Susanne [2 ]
Heller, Christine [3 ]
Sommerer, Patrick [4 ]
Kurnik, Karin [5 ]
机构：
[1] Vivantes Klinikum Friedrichshain, Berlin, Germany
[2] Univ Hosp Charite, Berlin, Germany
[3] Goethe Univ Frankfurt, Comprehens Care Ctr Thrombosis & Haemostasis, D-60054 Frankfurt, Germany
[4] CSL Behring GmbH, Marburg, Germany
[5] Univ Hosp Munich, Dr v Haunersches Childrens Hosp, Munich, Germany
来源：
HAEMOPHILIA | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：24 / 24
页数：1
相关论文
共 50 条
  • [31] Successful long-term treatment with porcine factor VIII of a patient with haemophilia A and an inhibitor to factor VIII
    Vyas, P
    Pasi, KJ
    Lee, CA
    HAEMOPHILIA, 1996, 2 (04) : 240 - 243
  • [32] Case study immune-tolerance in haemophilia a using plasma-derived factor VIII concentrate
    Needham, J.
    Roy, A.
    Knight, S.
    Stebbings, Y.
    Rangarajan, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1133 - 1134
  • [33] The safety of plasma-derived haemophilia factor concentrates - comments on "Deep viral metagenomics in patients with haemophilia receiving plasma-derived coagulation factor concentrates" Nunes Valenca I et al. (2021). Deep viral metagenomics in patients with haemophilia receiving plasma-derived coagulation factor concentrates. Haemophilia. https://doi.org/10.1111/hae.14382
    Farrugia, Albert
    HAEMOPHILIA, 2021, 27 (06) : E760 - E761
  • [34] Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A
    Dmoszynska, A.
    Kuliczkowski, K.
    Hellmann, A.
    Trelinski, J.
    Kloczko, J.
    Baglin, T.
    Hay, C.
    O'Shaughnessy, D.
    Zawilska, K.
    Makris, M.
    Shaikh-Zaidi, R.
    Gascoigne, E.
    Dash, C.
    HAEMOPHILIA, 2011, 17 (03) : 456 - 462
  • [35] THE CHOICE OF FACTOR-VIII CONCENTRATES FOR HIV-INFECTED HEMOPHILIACS - A RANDOMIZED STUDY COMPARING IMMUNOLOGICAL EFFECTS OF A VERY HIGH-PURITY AND A HIGH-PURITY FACTOR-VIII CONCENTRATE
    ROCINO, A
    QUIRINO, AA
    MIRAGLIA, E
    ZIELLO, L
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1035 - 1035
  • [36] Comparative effectiveness of plasma-derived and recombinant FVIII concentrates in the on-demand and prophylactic treatment of patients with haemophilia A
    Pollmann, H
    Richter, H
    Siegmund, B
    HAEMOPHILIA, 2004, 10 (05) : 676 - 678
  • [37] Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Haemate P) in von Willebrand Disease: A Systematic Review and Pharmacovigilance Update
    Ettingshausen, Carmen Escuriola
    Lassila, Riitta
    Escolar, Gines
    Male, Christoph
    Schirner, Kathrin
    Heyder, Lisa
    Berntorp, Erik
    HAEMOPHILIA, 2025, 31 (02) : 247 - 262
  • [38] Immune tolerance with a high purity plasma derived factor VIII containing von Willebrand factor in haemophilia A patients with high responding inhibitors.
    Polack, B
    Beurrier, P
    Rothschild, C
    Orsini, F
    Faradji, A
    Liennhard, A
    Fressinaud, E
    Goudemand, J
    BLOOD, 2004, 104 (11) : 846A - 846A
  • [39] Long-Term Follow-up of Patients with Congenital Thrombotic Thrombocytopenia Purpura Receiving Plasma-Derived Factor VIII Containing (Koate®)
    Chrisentery-Singleton, Tammuella
    Boggio, Lisa N.
    Carcao, Manuel
    Ibrahimi, Sami
    Khan, Osman
    Mahajerin, Arash
    Rajasekhar, Anita
    Sharma, Vivek
    Steele, MacGregor
    Torres, Marcela
    Carpenter, Shannon L.
    BLOOD, 2022, 140 : 5644 - 5646
  • [40] Preclinical development and characterization of a human plasma-derived high-purity factor X concentrate for therapeutic use
    Lloyd, Joanne
    Feldman, Peter
    HAEMOPHILIA, 2023, 29 (06) : 1394 - 1409
12345